Brilinta and Leukocytosis - a phase IV clinical study of FDA data

Summary:

Leukocytosis is reported as a side effect among people who take Brilinta (ticagrelor), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Metformin, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Leukocytosis when taking Brilinta. It is created by eHealthMe based on reports of 22,127 people who have side effects when taking Brilinta from the FDA, and is updated regularly.

What is Brilinta?

Brilinta has active ingredients of ticagrelor. It is often used in stent. eHealthMe is studying from 22,469 Brilinta users. Check the latest studies of Brilinta.

What is Leukocytosis?

Leukocytosis (increased white blood cells) is found to be associated with 1,342 drugs and 1,777 conditions by eHealthMe. Check the latest studies of Leukocytosis.

On Jul, 15, 2026

22,127 people reported to have side effects when taking Brilinta.
Among them, 14 people (0.06%) have Leukocytosis.

Among these 14 people:

How long have people been on Brilinta when they have Leukocytosis? *

What is the gender of people who have Leukocytosis when taking Brilinta? *

female: 28.57 %
male: 71.43 %

What is the age of people who have Leukocytosis when taking Brilinta? *

What are other drugs people take besides Brilinta? *

What are other side effects people have besides Leukocytosis? *

Acute Myocardial Infarction (acute heart attack): 6 people, 42.86%
Essential Hypertension (primary hypertension): 5 people, 35.71%
Drug Ineffective: 5 people, 35.71%
White Blood Cell Count Increased: 4 people, 28.57%
Sinusitis (inflammation of sinus): 4 people, 28.57%
Fever: 4 people, 28.57%
Hordeolum (small collection of pus (abscess) on the eyelid): 4 people, 28.57%
Eye Infection: 4 people, 28.57%
Extraocular Muscle Paresis (nerve paralysis outside of eye tissue): 4 people, 28.57%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 4 people, 28.57%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 4 people, 28.57%
Type 2 Diabetes: 1 person, 7.14%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 7.14%
Essential Hypertension (primary hypertension): 1 person, 7.14%
Chest Pain: 1 person, 7.14%
Cardiac Failure Chronic: 1 person, 7.14%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 1 person, 7.14%
Acute Coronary Syndrome (acute chest pain and other symptoms that happen because the heart does not get blood): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Brilinta and have Leukocytosis?

- Check whether Leukocytosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Brilinta:

Brilinta (22,469 reports)

Leukocytosis treatments and more:

Leukocytosis (22,918 reports)

Browse all side effects of Brilinta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Leukocytosis:

Leukocytosis (1,342 drugs)

Browse all the conditions that are associated with Leukocytosis:

Leukocytosis (1,777 conditions)

Related publications that referenced our studies

Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .
Khan A, Yasin Z, "Hyperleukocytosis Caused By Neulasta Complicated By Leukostasis Versus Asymptomatic Uncomplicated Hyperleukocytosis In AML. Two Cases and When To Leukapherese.", Am Soc Hematology, 2017 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ticagrelor (the active ingredients of Brilinta) and Brilinta (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.